• Immunic highlighted late-stage focus on oral immunology drugs led by vidofludimus calcium (IMU-838) for multiple sclerosis.
• Top-line data from Phase 3 ENSURE-1 and ENSURE-2 relapsing MS trials expected by end of 2026; an NDA targeted for mid-2027.
• Subject to regulatory approval, commercial launch targeted for 2028; peak sales potential estimated at USD 3-7 billion across RMS and PMS.
• Cash balance of USD 186.6 million as of March 31, 2026.
• Strategic alternatives under review to advance IMU-856 in celiac disease; Phase 3 program initiation in PPMS expected later in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.